1. Acknowledgement

   Acknowledgments 17 September 2012 Pages: 983 - 985

2. Does ‘NICE blight’ exist, and if so, why?

   • Alan Haycox

   Editorial 17 September 2012 Pages: 987 - 989

   

3. Modelling Downstream Effects in the Presence of Technological Change

   • Duncan Mortimer

   Current Opinion 17 September 2012 Pages: 991 - 1003

   

4. Measuring US Pharmaceutical Industry R&D Spending

   • Joseph Golec
   • John Vernon

   Leading Article 17 September 2012 Pages: 1005 - 1017

   

5. Management and Prevention of Diabetic Foot Ulcers and Infections

   • Ivy Chow
   • Elkin V. Lemos
   • Thomas R. Einarson

   Review Article 17 September 2012 Pages: 1019 - 1035

   

6. Single Technology Appraisals by NICE

   • Leela Barham

   Short Communication 17 September 2012 Pages: 1037 - 1043

   

7. A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy

   • Alec B. O’Connor
   • Katia Noyes
   • Robert G. Holloway

   Original Research Article 17 September 2012 Pages: 1045 - 1064

   

8. Essentials of Pharmacoeconomics

   • Christopher I. Carswell

   Book Review 17 September 2012 Pages: 1065 - 1065